Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, Acar O, Aksoy S, Baytemur NK, Sahin E, Cabuk D, Basaran G, Paydas S, Yaren A, Guven DC, Erdogan AP, Demirci U, Yasar A, Bayoglu İV, Hizal M, Gulbagci B, Paksoy N, Davarci SE, Yilmaz F, Dogan O, Orhan SO, Kayikcioglu E, Aytac A, Keskinkilic M, Mocan EE, Unal OU, Aydin E, Yucel H, Isik D, Eren O, Uluc BO, Ozcelik M, Hacibekiroglu I, Aydiner A, Demir H, Oksuzoglu B, Cilbir E, Cubukcu E, Cetin B, Oktay E, Erol C, Okutur SK, Yildirim N, Alkan A, Selcukbiricik F, Aksoy A, Karakas Y, Ozkanli G, Duman BB, Aydin D, Dulgar O, Er MM, Teker F, Yavuzsen T, Aykan MB, Inal A, Iriagac Y, Kalkan NO, Keser M, Sakalar T, Menekse S, Kut E, Bilgin B, Karaoglanoglu M, Sunar V, Ozdemir O, Turhal NS, Karadurmus N, Yalcin B, Nahit Sendur MA. Kahraman S, et al. Among authors: alkan a. Future Oncol. 2023 Mar;19(10):727-736. doi: 10.2217/fon-2022-1287. Epub 2023 May 3. Future Oncol. 2023. PMID: 37133230
Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience.
Bahçeci A, Paydaş S, Ak N, Ferhatoğlu F, Saip PM, Seydaoğlu G, Bilici M, Şimşek M, Tekin SB, Çalikuşu Z, Yavuz S, Şahin AB, Çubukçu E, Evrensel T, Değirmencioğlu S, Demiray AG, Yumuk PF, Alan Ö, Çikman Dİ, Demirelli FH, Köstek O, Gökyer A, Doğan M, Bal Ö, Çakar B, Gökmen E, Yamaç D, Korkmaz T, Aliyev A, Keskin Ö, Urvay S, Büyükşimşek M, Karadeniz C, Yildiz B, Çinkir HY, Demir H, Beypinar İ, Karaçin C, Eser K, Baykara M, Kiliçkap S, Okutur K, Bulut G, Alkan A, Arpaci E, Pilanci KN, Demir A, Işik D, Yildirim N. Bahçeci A, et al. Among authors: alkan a. Cancer Invest. 2021 Jul-Aug;39(6-7):473-481. doi: 10.1080/07357907.2021.1933011. Epub 2021 Jun 7. Cancer Invest. 2021. PMID: 34014777
Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG).
Türkkan G, Alkan A, Paydaş S, Tanrıverdi Ö, Karakaş Y, Karadurmuş N, Sakin A, Temiz S, Arpacı E, Akın M, Menekşe S, Şen CA, Barışta İ. Türkkan G, et al. Among authors: alkan a. Indian J Hematol Blood Transfus. 2020 Oct;36(4):640-645. doi: 10.1007/s12288-020-01257-0. Epub 2020 Feb 22. Indian J Hematol Blood Transfus. 2020. PMID: 33100705 Free PMC article.
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Tural D, Ölmez ÖF, Sümbül AT, Özhan N, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S, Artaç M. Tural D, et al. Among authors: alkan a. Int J Clin Oncol. 2021 Aug;26(8):1506-1513. doi: 10.1007/s10147-021-01936-6. Epub 2021 May 23. Int J Clin Oncol. 2021. PMID: 34023933
Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG).
Oktay E, Levent M, Gelincik H, Aktaş G, Yumuk F, Koral L, Arpacı E, Keser M, Alkan A, Karci E, Karadurmuş N, Degirmencioglu S, Turan M, Uyeturk U, Cabuk D, Avci N, Toprak O, Ergen A, Urvay S, Bayman E, Petekkaya E, Nayir E, Paydaş S, Yavuzsen T, Senler FC, Yaren A, Barutca S, Şahinler İ, Ozyilkan O, Tanriverdi O. Oktay E, et al. Among authors: alkan a. J Cancer Educ. 2020 Feb;35(1):69-75. doi: 10.1007/s13187-018-1441-6. J Cancer Educ. 2020. PMID: 30446981
Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG).
Alkan A, Yaşar A, Güç ZG, Gürbüz M, Başoğlu T, Sezgin Göksu S, Buğdaycı Başal F, Türk HM, Özdemir Ö, Yeşil Çınkır H, Güven DC, Kuş T, Türker S, Koral L, Karakaş Y, Ak N, Paydaş S, Karcı E, Demiray AG, Demir A, Alan Ö, Keskin Ö, Nayır E, Tanrıverdi Ö, Yavuzşen T, Yumuk PF, Ateş Ö, Coşkun HŞ, Turhal S, Çay Şenler F. Alkan A, et al. Eur J Cancer Care (Engl). 2020 Nov;29(6):e13296. doi: 10.1111/ecc.13296. Epub 2020 Aug 30. Eur J Cancer Care (Engl). 2020. PMID: 32864838
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D, Ölmez ÖF, Sümbül AT, Artaç M, Özhan N, Akar E, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Yılmaz U, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S. Tural D, et al. Among authors: alkan a. Eur Urol Focus. 2021 Sep;7(5):1061-1066. doi: 10.1016/j.euf.2020.09.010. Epub 2020 Sep 30. Eur Urol Focus. 2021. PMID: 33008789
The role of ABO blood groups in glial neoplasms.
Alkan A, Yazıcı G, Cengiz M, Karakaş Y, Çelik İ, Kars A, Zorlu F. Alkan A, et al. Br J Neurosurg. 2019 Feb;33(1):43-46. doi: 10.1080/02688697.2018.1522415. Epub 2018 Nov 4. Br J Neurosurg. 2019. PMID: 30394124
458 results